Shares of Solara Active Pharma Sciences Ltd surged nearly 4% to ₹523.35 on Monday after the company announced that its Ambernath manufacturing facility in Maharashtra has successfully cleared a US Food and Drug Administration (USFDA) inspection with zero observations.
The USFDA conducted a comprehensive inspection of the site from May 5 to May 9, 2025. According to Solara, the agency concluded the inspection without issuing any Form 483 observations, indicating full compliance with regulatory requirements. This is the third consecutive zero-observation inspection outcome across Solara’s manufacturing network.
Commenting on the update, Sandeep Rao, Managing Director and CEO of Solara, said, “We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This demonstrates our commitment to regulatory excellence and reinforces our focus on world-class quality and compliance, which remain key pillars of our growth strategy.”
Solara’s stock opened at ₹71.53 and traded strongly through the morning, hitting a high of ₹524.00. The market cap of the company now stands at ₹28.48 billion.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
